Despite treatment with temozolomide and radiation therapy, patients with glioblastoma usually develop refractory disease, and thus have a poor prognosis (median overall survival of 15 months); here, the DNA damage response (DDR) mechanism shown by cancer cells plays a key role.
Ariceum Therapeutics GmbH has submitted an application with the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial of [123I]-ATT-001, its iodine-123-labeled PARP inhibitor in patients with recurrent glioblastoma.
Carthera SA received an additional €4.5 million (US$4.9 million) from investors to take its series B funding round to €42 million despite a tough fundraising environment for med-tech companies. Frédéric Sottilini, CEO of Carthera, told BioWorld that the strong investor interest was testament to their confidence in the company’s Sonocloud technology for brain disorder treatment.
Katy Rezvani received this year’s E. Donnall Thomas Prize for her work on natural killer (NK) cells at the annual meeting of the American Society of Hematology (ASH). It was not love at first sight, though.
One of the difficulties for preventing the evolution of a tumor is that cancer progression can be promoted by undifferentiated or migrating cells whose states could follow different directions. At the 40th edition of Barcelona Biomed conferences at the Institute for Research in Biomedicine (IRB Barcelona), which took place from Nov. 27 to 29, 2023, and is entitled “Cancer in Context: Cellular, Tissue, and Organismal Determinants of Malignant Fates,” Angela Nieto presented her latest data on epithelial-to-mesenchymal transition (EMT).
Invios GmbH and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate Invios' immune-activating small molecule, INV-501, as a potential treatment for glioblastoma.
Disappointing preliminary top-line data from Kintara Therapeutics Inc.’s phase II/III study of VAL-083 (dianhydrogalactitol) is causing the company to shift its attention and resources to another cancer program. In the meantime, the results wreaked havoc on the stock and sent the company on a mission to look at its options.
The FDA has accepted Mustang Bio Inc.’s IND application of MB-109 for the treatment of recurrent glioblastoma (GBM) and high-grade astrocytoma. MB-109 is a treatment regimen combining MB-101 (City of Hope-developed IL13Rα2‐targeted CAR T-cell therapy) and MB-108 (Nationwide Children’s Hospital-developed HSV-1 oncolytic virus).
Researchers from Guangdong University of Technology have reported the discovery of novel fibroblast growth factor receptor 1 (FGFR1) inhibitors as potential candidates for the treatment of glioblastoma multiforme (GBM).
Chimeric Therapeutics Ltd.‘s chlorotoxin (CLTX) CAR T therapy, CHM-1101, which is derived from scorpion toxin, saw a disease control rate of 55%, exceeding the historical disease control rates of 20% to 37% in heavily pre-treated patients with glioblastoma.
